Amino Acid Metabolism Disorders Treatment Market Research, 2031
The global amino acid metabolism disorders treatment market was valued at $630.9 million in 2021, and is projected to reach $961.8 million by 2031, growing at a CAGR of 4.3% from 2022 to 2031. The amino acid metabolism is a significant process that occurs within the human body to assist in numerous biological reactions. The disorders that affect the metabolism of amino acids include phenylketonuria, tyrosinemia, homocystinuria, non-ketotic hyperglycinemia, and maple syrup urine disease. These disorders are autosomal recessive, and may be diagnosed by analyzing amino acid concentrations in body fluids. In that, maple syrup urine disease can also feature the production of organic acids. The amino acids are the building blocks that join together to form proteins. There may also be a problem getting the amino acids into the cells. These problems cause a buildup of harmful substances in the body. This further can lead to serious, sometimes life-threatening, health problems. The treatments for this usually includes special diets, medicines, and supplements. Some babies may also need additional treatments if there are complications.
Growth of the amino acid metabolism disorders treatment market size is driven by increase in prevalence of amino acid metabolism disorders such as maple syrup urine disease, phenylketonuria, and citrullinemia high cost of treatments, rise in research and development activities on amino acid metabolism disorders treatment, increased disposable income in developing countries and development of healthcare infrastructure.
However, increase in cost of amino acid supplement, lack of awareness of amino acid metabolism disorders and associated side effects of phenylketonuria injections are negatively impacting the market growth. Conversely, increase in the healthcare expenditure offers amino acid metabolism disorders treatment market opportunity for the growth of the market.
Impact of COVID-19 Pandemic on Amino acid Metabolism Disorders Treatment Market Size
Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The situation of COVID-19 has varied outcome when related to vaccinations. There is an emerging gap in the economic recovery between high-income and low and middle income countries. After the pandemic severely disrupted global trade, the world is witnessing a robust rebound, which is helping with the recovery in the year 2021. Trade contributes to speeding up economic recovery from the pandemic by providing sustained foreign demand for exports and ensuring the availability of imported intermediate products and services. The COVID-19 pandemic affected the amino acid metabolism disorders treatment industry in a negative way, like various other pharmaceutical industries were affected. This was due to the significant decline in demand for the amino acid metabolism disorders treatments across several sectors, particularly the health and pharmaceutical sector. The main cause of the interruptions experienced by government, as government was majorly involved in the disease spread preventive measures finding. As a result, the COVID-19 outbreak will slow down the growth for amino acid metabolism disorders treatment industry, which will have a negative effect on the market's value in 2022 and beyond.
Amino Acid Metabolism Disorders Treatment Market Segmentation
The amino acid metabolism disorders treatment market is segmented into Product Type, Indication, and Distribution channel. The amino acid metabolism disorders treatment market is segmented into product type, indication, distribution channel, and region. By product type, the market is categorized into folic acid, Vitamin B6 and B12, arginine, thiamine, betaine, sapropterin, and others. On the basis of indication, the market is categorized into phenylketonuria, maple syrup urine disease, citrullinemia, homocystinuria, and argininosuccinic aciduria. Based on distribution channel, the market is categorized into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment is further subcategorized as prescription drug and OTC drug. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa and rest of LAMEA).
Market By Product Type Segment Review
By product type, the market is divided into folic acid, vitamin B6 and B12, arginine, thiamine, betaine, sapropterin, and others. The sapropterin segment exhibited the highest growth in 2021, owing to increase in prevalence of phenylketonuria and increase in demand for sapropterin in developed countries such as the U.S. and Germany. However, betaine segment is expected to register highest CAGR of 5.4% from 2022-2031, owing to increase in product offering for betaine by key market players.
Market By Indication Segment Review
By indication, the market is classified as phenylketonuria, maple syrup urine disease, citrullinemia, homocystinuria, and argininosuccinic aciduria. The phenylketonuria segment exhibited the highest growth in 2021, owing to increase in prevalence of phenylketonuria and mandatory newborn screening for the diagnosis of phenylketonuria and other amino acid metabolism disorders. However, maple syrup urine disease segment is expected to register highest CAGR of 5.5% from 2022 to 2031, owing to increase in prevalence of maple syrup urine disease and development of new therapies for the treatment of maple syrup urine disease.
Market By Distribution Channel Segment Review
By distribution channel, the market is classified as hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment dominated the amino acid metabolism disorders treatment market share in 2021 and is expected to remain dominant during the forecast period. The amino acid metabolism disorders treatment market growth of this segment driven by increased sell of prescription drugs and OTC drugs. However, online providers is expected to register highest CAGR of 6.0% from 2022- 2031, owing to shift of patients preference to buy medicine online since the COVID-19 pandemic period.
Market By Region Review
Region wise, North America had the highest amino acid metabolism disorders treatment market share in 2021, and is expected to maintain its lead during the forecast period, owing to increase in demand for sapropterin and Kuvan for amino acid metabolism disorders treatments. Moreover, the North America advances due to availability of treatments and well established healthcare infrastructure. However, Asia-Pacific is expected to register highest CAGR of 5.5% during the amino acid metabolism disorders treatment market forecast period, owing to increase in prevalence amino acid metabolism disorders and rise in patients seeking treatment for amino acid metabolism disorders.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the amino acid metabolism disorders treatment market analysis from 2021 to 2031 to identify the prevailing amino acid metabolism disorders treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the amino acid metabolism disorders treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global amino acid metabolism disorders treatment market trends, key players, market segments, application areas, and market growth strategies.
Amino acid Metabolism Disorders Treatment Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 961.8 million |
 Growth Rate | CAGR of 4.3% |
 Forecast period | 2021 - 2031 |
 Report Pages | 350 |
 By Indication |
|
 By Product |
|
 By Distribution channel |
|
 By Region |
|
 Key Market Players | BioMarin Pharmaceutical Inc., AMINO GmbH, Pfizer, Inc., Shine Star (Hubei) Biological Engineering Co., Recordati S.p.A., Teva Pharmaceutical Industries Ltd., Civentichem, LLC, Ltd., Sanofi, Merck KGaA, Kyowa Hakko Kirin Co., Ltd., Koninklijke DSM N.V., GlaxoSmithKline PLC |
Analyst Review
The global amino acid metabolism disorders treatment market is expected to exhibit high growth potential attributable to factors such as increase in prevalence of amino acid metabolism disorders, rise in R&D activities in drug discovery & development, and increase in awareness about early diagnostic methods. Moreover, surge in treatment developments for amino acid metabolism disorders contribute toward the growth of the market.
The amino acid metabolism treatment drugs helps in maintaining required level of amino acids. Folic acid helps to convert methionine into homocysteine essential for homocystinuria treatment. Furthermore, North America is expected to witness the highest growth, in terms of revenue, owing to rise in prevalence of phenylketonuria, maple syrup urine disease, and citrullinemia; rise in healthcare expenditure; and strong presence of key players. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in research and development activities for amino acid metabolism disorders treatment and unmet medical demands during the forecast period.
The forecast period for amino acid metabolism disorders treatment market is 2022-2031
The key trends of amino acid metabolism disorders treatment market include the increase in prevalence of amino acid metabolism disorders such as maple syrup urine disease, phenylketonuria, and citrullinemia high cost of treatments, rising research and development activities on amino acid metabolism disorders treatment, increased disposable income in developing countries and development of healthcare infrastructure.
The total market value of Amino acid Metabolism Disorders Treatment Market report in 2031 is expected to be $961.75 Million.
The largest regional market for Amino acid Metabolism Disorders Treatment is North America.
Asia-Pacific is expected to register highest CAGR of 5.5% from 2022 to 2031.
Yes, the amino acid metabolism disorders treatment market companies are profiled in the report.
The base year calculated in the amino acid metabolism disorders treatment market report in 2021.
Yes, the amino acid metabolism disorders treatment market report provides the PORTER analysis.
Loading Table Of Content...
